Cyclomics specializes in advanced molecular diagnostics using Nanopore sequencing and proprietary molecular assays to detect and monitor cancer through the analysis of circulating tumor DNA from liquid biopsies. This technology enables real-time, non-invasive cancer detection, providing precise insights into tumor dynamics and treatment efficacy, ultimately improving patient outcomes.
Funding
$81.9K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional cancer detection methods often rely on invasive tissue biopsies, which can be risky, uncomfortable, and may not fully represent the tumor's heterogeneity or track real-time changes. Monitoring treatment efficacy and detecting recurrence requires frequent biopsies, increasing patient burden and healthcare costs.
Solution
Cyclomics offers a non-invasive cancer monitoring solution using liquid biopsies and Nanopore sequencing to analyze circulating tumor DNA (ctDNA). Their proprietary molecular assays and consensus sequencing technology enable highly sensitive and accurate detection of genetic variations in ctDNA, providing real-time insights into tumor dynamics. This approach allows for early cancer detection, precise monitoring of treatment response, and timely identification of recurrence, all from a simple blood draw. By leveraging multi-omics data and AI, Cyclomics aims to improve patient outcomes through personalized and informed treatment decisions.
Target Audience
Cyclomics targets oncologists, pathologists, and pharmaceutical companies involved in cancer research and treatment, as well as patients seeking less invasive and more informative diagnostic options.
Features
- Non-invasive cancer detection and monitoring using liquid biopsies
- Nanopore sequencing for high-throughput analysis of ctDNA
- Proprietary molecular assays for enhanced sensitivity and specificity
- Consensus sequencing to accurately identify and confirm genetic variations
- Real-time monitoring of tumor dynamics and treatment efficacy
- Multi-omics data integration for a holistic view of cellular functions and disease mechanisms
- AI-powered analysis for uncovering hidden patterns and generating actionable insights